Business
Alnylam Presents Positive Complete Results from ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria
− Givosiran Achieved a 74 Percent Mean Reduction in Composite Annualized Attack Rate (AAR) Relative to Placebo, with Consistent Reductions Across all
About this update from Alnylam Pharmaceuticals, Inc.
[{"type":"text","content":"− Givosiran Achieved a 74 Percent Mean Reduction in Composite Annualized Attack Rate (AAR) Relative to Placebo, with Consistent Reductions Across all Components of Composite Endpoint and Subgroups -− Treatment Effect Includes a 90 Percent Median Decrease in Composite AAR Relative to Placebo, with 50 Percent of Givosiran Patients Attack-Free -− Ninety-Nine Percent of Patients Enrolled in Open-Label Extension Study -− Alnylam to Host Conference Call Saturday, April 13th at 8:00 am ET -CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today positive complete results from the ENVISION Phase 3 study of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) in development for the treatment of acute hepatic porphyria (AHP). The clinical data are being presented in an oral presentation at the European Association for the Study of the Liver (EASL) International Liver Congress™ being held April 10-14 in Vienna, Austria.The full ENVISION results demonstrated a 74 percent mean and 90 percent median reduction in the primary endpoint measure of annualized rate of composite attacks in patients on givosiran relative to placebo during the six-month double-blind period. In addition, givosiran achieved statistically significant positive results for five of nine secondary endpoints, with an overall safety and tolerability profile that the Company believes is encouraging, especially in this high unmet need disease. Adverse events (AEs) were reported in 89.6 percent of givosiran patients and 80.4 percent of placebo patients; serious adverse events (SAEs) were reported in 20.8 percent of givosiran patients and 8.7 percent of placebo patients. Ninety-three of 94 patients, or 99 percent, enrolled in the open-label extension (OLE) period of the study. Based on the ENVISION results, the Company plans to complete its rolling submission of a New Drug Application (NDA) and file a Marketing Authorisation Application (MAA) in mid-2019.\"Given the high unmet need in this disease setting, we are very pleased for the patients and families living with acute hepatic porphyria for whom these results signal hope for a potential new therapeutic option,\" said Akshay Vaishnaw, M.D., Ph.D., President of R&D at Alnylam. \"Givosiran substantially reduce...